A drug bulletin reviewing bremelanotide for HSDD following FDA approval. Summarizes mechanism, efficacy from phase 3 trials, adverse effects, cost, and place in therapy relative to flibanserin. Provides a concise clinical reference for prescribers newly encountering this drug.